Sequence: trimeric cyclic RGD
| Experiment Id | EXP000678 |
|---|---|
| Paper | Direct Cytosolic Delivery of siRNA Conjugates: A Paradigm in Antiangiogenic Therapy for Choroidal Ne |
| Peptide | TriRGD |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | covalent conjugate |
| Rna Concentration | 10 nM |
| Mixing Ratio | covalent |
| Formulation Format | siRNA conjugate |
| Formulation Components | TriRGD–siRNA–fluorinated |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HUVEC-Luc |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockdown |
| Output Value | Significant VEGF/VEGFR2 silencing |
| Output Units | |
| Output Notes | Efficient cellular uptake; fluorinated systems show cytosolic distribution |
| Toxicity Notes | No significant cytotoxicity |
| Curation Notes |